Santarus Makes Phase III HAE, Pharming for Harvest in Acute
By Randy Osborne and Cormac Sheridan
Wednesday, November 14, 2012
Poised to wade into a crowded field of drugs for hereditary angioedema (HAE), Santarus Inc. and partner Pharming Group NV said last week the pivotal Phase III study with the C1 esterase inhibitor Ruconest for acute HAE attacks met the primary endpoint of time to beginning of symptom relief.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.